These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35207375)

  • 1. Severe Thrombotic Thrombocytopenic Purpura (TTP) with Organ Failure in Critically Ill Patients.
    Fodil S; Zafrani L
    J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
    Hollifield AL; Arnall JR; Moore DC
    Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in thrombotic thrombocytopenic purpura.
    Sadler JE; Moake JL; Miyata T; George JN
    Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac implications of thrombotic thrombocytopenic purpura.
    Wiernek SL; Jiang B; Gustafson GM; Dai X
    World J Cardiol; 2018 Dec; 10(12):254-266. PubMed ID: 30622684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathogenesis and novel treatment of thrombotic thrombocytopenic purpura].
    Matsumoto M
    Rinsho Ketsueki; 2021; 62(5):480-485. PubMed ID: 34248125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnosis and treatment of thrombotic thrombocytopenic purpura].
    Kubo M; Matsumoto M
    Rinsho Ketsueki; 2020; 61(5):529-535. PubMed ID: 32507820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombotic thrombocytopenic purpura.
    Joly BS; Coppo P; Veyradier A
    Blood; 2017 May; 129(21):2836-2846. PubMed ID: 28416507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab.
    Mellaza C; Henry N; Fayolle PM; Mortaza S; Subra JF; Veyradier A; Coppo P; Augusto JF
    Front Med (Lausanne); 2020; 7():549931. PubMed ID: 33195299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unresponsive thrombotic thrombocytopenic purpura in critically ill adults.
    Mariotte E; Blet A; Galicier L; Darmon M; Parquet N; Lengline E; Boutboul D; Canet E; Traineau R; Schlemmer B; Veyradier A; Azoulay E
    Intensive Care Med; 2013 Jul; 39(7):1272-81. PubMed ID: 23549631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification.
    Shenkman B; Einav Y
    Autoimmun Rev; 2014; 13(4-5):584-6. PubMed ID: 24418304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
    Furlan M; Lämmle B
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe HELLP syndrome masquerading as thrombocytopenic thrombotic purpura: a case report.
    Mousseaux C; Joly BS; Mohamadou I; Arrestier R; Hertig A; Rafat C
    BMC Nephrol; 2020 May; 21(1):204. PubMed ID: 32471388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.
    Elverdi T; Eskazan AE
    Drug Des Devel Ther; 2019; 13():1251-1258. PubMed ID: 31118566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and Management of Thrombotic Thrombocytopenic Purpura in the Emergency Department.
    Long B; Bridwell RE; Manchanda S; Gottlieb M
    J Emerg Med; 2021 Dec; 61(6):674-682. PubMed ID: 34518045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
    Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
    N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
    Moake JL; McPherson PD
    Am J Med; 1989 Sep; 87(3N):9N-15N. PubMed ID: 2486537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
    Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
    Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive Response and Increase in ADAMTS13 with Scheduled Rituximab in a Patient with Relapsing Thrombotic Thrombocytopenic Purpura.
    Amer B; Patel A
    Cureus; 2019 Jul; 11(7):e5054. PubMed ID: 31516768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura.
    Hanlon A; Metjian A
    Ther Adv Hematol; 2020; 11():2040620720902904. PubMed ID: 32095224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura.
    Jilma-Stohlawetz P; Gorczyca ME; Jilma B; Siller-Matula J; Gilbert JC; Knöbl P
    Thromb Haemost; 2011 Mar; 105(3):545-52. PubMed ID: 21174003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.